69 reports

  • RECENT PARTNERSHIPS: POPULAR DISEASE INDICATIONS

OTHER POPULAR THERAPEUTIC AREAS FOR WHICH SUCH CELL THERAPIES ARE BEING DEVELOPED INCLUDE CANCER (##), EYE DISORDERS (##), NEUROLOGICAL DISORDERS (##), AND GENETIC DISORDERS (##).

  • Hospital
  • Psychotic Disorder
  • United States
  • Erytech Pharma SA
  • Neurotech Pharmaceuticals, Inc.
  • B. Introduction to CNS Disorders

The main causes of ADHD are not clear, many studies have suggested that the genetic makeup of the patient plays an important role in this disease.

  • Hospital
  • Psychotic Disorder
  • AstraZeneca PLC
  • Lilly Endowment Inc.
  • Pfizer Inc.

" This marks a transition in how we can use large genetic studies to understand the biology of disease.

  • Cancer
  • Psychotic Disorder
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

Gaucher disease is a genetic disorder in which a fatty substance called glucosylceramide accumulates in certain tissues and organs.

  • Psychotic Disorder
  • Brazil
  • World
  • Product Initiative
  • Protalix BioTherapeutics, Inc.

Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Genzyme Corporation

This report is a licensed product and is not to be photocopied Teva Pharmaceutical Industries Limited - Research and Development Overview Teva Pharmaceutical Industries Limited has promising clinical drug candidates for ## major therapeutic areas, Central Nervous System, Infectious Disease,

  • Psychotic Disorder
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited
  • Products under Development by Companies, H2 2018

Gaucher disease is a genetic disorder in which a fatty substance called glucosylceramide accumulates in certain tissues and organs.

  • Gene Therapy
  • Psychotic Disorder
  • Therapy
  • Brazil
  • Protalix BioTherapeutics, Inc.

The company will also take part in the CTAD (Clinical Trial on Alzheimer' s Disease) conference in Boston, United States, from ##-## November.

  • Healthcare
  • Pharmaceutical
  • Psychotic Disorder
  • France
  • Pharnext

TABLE OF CONTENTS ##.

  • Psychotic Disorder
  • United States
  • genOway SA
  • Lexicon
  • Taconic Farms, Inc.

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United Kingdom
  • Heptares Therapeutics Limited
  • APR 17, 2017: AMARANTUS FORMS SUBSIDIARIES "ELTO PHARMA" TO FOCUS ON CNS DISORDERS AND "MANF THERAPEUTICS" TO FOCUS ON OPHTHALMOLOGY

MANF has demonstrated positive pre-clinical data in a number of models of retinitis pigmentosa including, a chronic degenerative genetic disorder.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Amarantus BioScience Holdings, Inc.
  • May 10, 2018: Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results

Characterized as an autism spectrum disorder, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in ##, ## live births.

  • Dementia
  • Psychotic Disorder
  • United States
  • Company
  • Anavex Life Sciences Corp.

The disease can be genetically inherited or caused by unknown factors.

  • Psychotic Disorder
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.

Each unit consists of one share of common stock and one series A warrant to purchase one share of common stock.

  • Cell Therapy
  • Psychotic Disorder
  • United States
  • Company Financials
  • ISCC

The company offers raw genetic data and ancestry-related genetic reports.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Lundbeck Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • TORAY INDUSTRIES INC

Patients will be randomized ##:## to receive either a six-week course of NFC-## or placebo, with a one-week follow-up. ##-May-2016 Medgenics, Inc. registered a Phase II/ III multicenter, ##-week, double-blind, randomized, placebocontrolled, parallel-design study t

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Addex Therapeutics Ltd
  • MAR 07, 2018: ANAVEX LIFE SCIENCES TO PRESENT NEW PRECLINICAL DATA AT THE 20TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS (ASENT)
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Characterized as an autism spectrum disorder, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in ##, ## live births.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Anavex Life Sciences Corp.

TO DEMONSTRATE GENETIC STRATIFICATION OF DRUG RESPONSE IN IL-## IMPLICATED EYE DISEASE.

  • Clinical Trial
  • Hospital
  • Mental Health
  • Psychotic Disorder
  • AutoGenomics, Inc.
  • The U.S. Schizophrenia Patient Population (2014-2018)
  • 3.2 Europe

In non-identical twins, who have different genetic make-ups, when one twin develops schizophrenia, the other only has a one in seven chance of developing the condition.

  • Mental Health
  • Psychotic Disorder
  • World
  • Forecast
  • Otsuka Pharmaceutical Co., Ltd.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones

Characterized as an autism spectrum disorder, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in ##, ## live births.

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Anavex Life Sciences Corp.

HD is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain.

  • Mental Health
  • Pharmaceutical
  • Psychotic Disorder
  • Canada
  • NEMUS Bioscience, Inc.
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development

Patients will be randomized ##:## to receive either a six-week course of NFC-## or placebo, with a one-week follow-up. ##-May-2016 Medgenics, Inc. registered a Phase II/ III multicenter, ##-week, double-blind, randomized, placebocontrolled, parallel-design study t

  • Psychotic Disorder
  • Therapy
  • United States
  • World
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Patients will be randomized ##:## to receive either a six-week course of NFC-## or placebo, with a one-week follow-up. ##-May-2016 Medgenics, Inc. registered a Phase II/ III multicenter, ##-week, double-blind, randomized, placebocontrolled, parallel-design study t

  • Neurological Disorder
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Global Markets Direct Report Coverage

Its products are used in the treatment of diseases such as Alzheimers disease, depression, Parkinsons disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntingtons disease among others.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Introduction
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones

Patients will be randomized ##:## to receive either a six-week course of NFC-## or placebo, with a one-week follow-up. ##-May-2016 Medgenics, Inc. registered a Phase II/ III multicenter, ##-week, double-blind, randomized, placebocontrolled, parallel-design study t

  • Psychotic Disorder
  • Research And Development
  • World
  • Product Initiative
  • Addex Therapeutics Ltd

We are very pleased that FDA has recognized the potential benefit of BPN## in the treatment of Fragile X Syndrome, a genetic disorder for which there is neither a cure nor any approved therapy, " said Mark E.

  • Healthcare
  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Company
  • PIPELINE BY H. LUNDBECK AS, H1 2018
  • PIPELINE BY IONIS PHARMACEUTICALS INC, H1 2018

Its products are used in the treatment of diseases such as Alzheimers disease, depression, Parkinsons disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntingtons disease among others.

  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Oncodesign SA

In part ##, patients will be randomized on a ##:##:## basis to receive one of two active doses (## mg or ## mg) of PRX##/ RG## or placebo via intravenous infusion once every ## weeks.

  • Monoclonal Antibody
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones

Characterized as an autism spectrum disorder, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in ##, ## live births.

  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Anavex Life Sciences Corp.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones

Characterized as an autism spectrum disorder, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in ##, ## live births.

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Anavex Life Sciences Corp.